MATTERS develops educational materials for partners and community members to utilize across our networks. Explore our resource library below and use the search function to find what you’re looking for even faster.
22 documents
Cycle of Addiction
Understanding the cycle of addiction can help when addressing substance use disorder.
Exposure to Opioids via Cocaine
Drugs like fentanyl are contaminating stimulants across the United States.
Facts on Fentanyl
Fentanyl is a potent, synthetic opioid that is contaminating other drugs in the U.S. drug supply.
Facts on Xylazine
Xylazine is a potent veterinary tranquilizer that is contaminating opioids across the U.S.
Gas Station Heroin: The Dangers of Tianeptine
Tianeptine is an emerging risk to public health due to its potential for misuse and widespread availability.
Language MATTERS
Reduce stigma against people who use drugs (PWUD) by adjusting your language.
Medetomidine
Medetomidine is a potent sedative-analgesic contributing to a recent wave of overdoses.
Myth Busting Fentanyl Exposure
Dispel common myths and misconceptions around fentanyl exposure risks.
Myth Busting Syringe Exchange Programs
Syringe Services are an example of evidence-based harm reduction strategies.
Resources for Prescribers
Navigate the documents below to review current prescribing guidelines, exemptions, and frequently asked questions.
6 documents
Buprenorphine & Referral Protocol
MATTERS developed a suggested buprenorphine induction protocol as part of its referral process to support providers in linking patients to medication for addiction treatment (MAT).
DEA Instructions
The DEA released instructions on how to request an extension for practitioners administering or dispensing certain medications for opioid use disorder (MOUD).
Notice to Patients: Opioid and Sedative Medications
MATTERS has developed a patient notice for opioid and sedative prescribing to help them understand the risks of misusing these substances.
Opioid and Sedative Prescribing Guidelines
MATTERS provides guidelines for opioid and sedative prescribing for new providers or those who are new to prescribing controlled substances such as buprenorphine.
Prescribing FAQs
Since the repeal of the X-Waiver, many providers are eligible to prescribe buprenorphine to treat opioid use disorder. Learn more about prescribing requirements by navigating our frequently asked questions.
Telemedicine Protocol
Walk through how to connect individuals to care from anywhere with MATTERS’ telemedicine protocol.